Breaking Finance News

RBC Capital announced Valeant Pharma (NYSE:VRX), dropping its stock price target to $35.00 today

In a report released on 10/12/2016 RBC Capital reduced the stock price target of Valeant Pharma (NYSE:VRX) from $36.00 to $35.00 indicating a possible upside of 0.53%.

Yesterday Valeant Pharma (NYSE:VRX) traded -2.76% lower at $22.94. The company’s 50-day moving average is $27.32 and its 200-day moving average is $26.95. The last stock close price is down -14.87% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 10,651,664 shares of the stock were exchanged, down from an average trading volume of 23,550,900

See Chart Below

Valeant Pharma (NYSE:VRX)

Valeant Pharma has a with a one year low of $18.55 and a one year high of $179.83 Valeant Pharma’s market capitalization is presently $0.

A total of 18 analysts have released a report on Valeant Pharma. Three analysts rating the company a strong buy, 2 brokers rating the stock a buy, 10 brokers rating the stock a hold, 4 brokerages rating the stock a underperform, and finally 1 brokerage rating the stock a sell with a average stock price target of $43.56.

Brief Synopsis On Valeant Pharma (NYSE:VRX)

Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It operates through two segments: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses on primarily on branded generics, OTC products and medical devices. Its pharmaceutical products include Xifaxan, Solodyn and Glumetza. Its OTC products include PreserVision, CeraVe, Biotrue and Boston. Its other generic products include Latanoprost and Metronidazole. Its ophthalmic surgical products include intraocular lenses, such as Akreos, enVista, Crystalens and Trulign.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *